On November 20, 2024, Acurx pharmaceuticals announced that it approved the conversion of a portion of its cash reserves into Bitcoin, up to a maximum of $1 million.
Immediately, the stock plunged, reflecting shareholder disapproval of this decision. Since then, Acurx has lost around 58% of its value.
To me, this reaction is disproportionate for several...
